No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 3.060
- +0.120+4.08%
Trading Apr 30 11:07 ET
215.53MMarket Cap-10551P/E (TTM)
3.070High2.880Low8.06KVolume2.950Open2.940Pre Close23.94KTurnover0.02%Turnover RatioLossP/E (Static)70.44MShares4.00052wk High2.61P/B124.57MFloat Cap0.97052wk Low--Dividend TTM40.71MShs Float10.620Historical High--Div YieldTTM6.46%Amplitude0.460Historical Low2.971Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic
Trevi Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 155.18% Needham → $8 Reiterates Buy → Buy 03/21/2024 187.08% Oppenheimer $9 → $9 Maintains Outp
CALM,PLAY and VNDA Are Among After Hour Movers
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)
Buy Rating for Trevi Therapeutics Anchored on Haduvio's Clinical Promise and Market Potential
Trevi Therapeutics Is Maintained at Outperform by Oppenheimer
Trevi Therapeutics Is Maintained at Outperform by Oppenheimer
Comments
Update
$Trevi Therapeutics(TRVI.US$ Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) 2 MINUTES AGO, 7:30 AM EST VIA PR NEWSWIRE
1
6
Update
$Trevi Therapeutics(TRVI.US$ Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis 5 MINUTES AGO, 8:30 AM EDT VIA PR NEWSWIRE TRVI SHARE Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety data Preliminary analyses presented at the European Academy of Dermatology & V...
$Trevi Therapeutics(TRVI.US$ Long Buyers better Sell Off and enjoy your Gain 🤗👌👍, if greedy then check CS & BXRX 😏😩😪
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Massinooo : Is this ticker good to trade?
TrytosaveabitOP Massinooo: It will be eventually! Im still looking for bottom?
Massinooo : I have it for 1.16 you think I should hold?
TrytosaveabitOP Massinooo: If you don’t mind averaging down some if need be? Im sorry! I just can’t say whether to buy or sell? I only say what I’m doing! I would hate to be responsible for someone losing! Grrr! Sorry but I’m rooting for you!
Massinooo : Totally understand bro. I’ll keep an eye on it after market opens and will decide. Thank you bro
View more comments...